Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Baraclude

- PMLiVE

GSK tops Access to Medicines Index for fifth time running

Leads J&J and Novartis in 'needs-orientation' while Roche and Astellas lag

- PMLiVE

Teva expands eHealth alliance with IBM

Taps Watson Health Cloud for drug development and disease management work

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

- PMLiVE

Teva appoints UK & Ireland general manager

Promotes UK chief operating officer Kim Innes

- PMLiVE

Could Gilead face early Sovaldi generics in Europe?

EU patent protection for the hepatitis C virus drug will end in 2024

- PMLiVE

Teva sells UK and Ireland assets to Intas Pharma for £603m

Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

- PMLiVE

Pfizer decides against long-discussed break-up

Says dividing its R&D and generics businesses would disrupt rather than create value

- PMLiVE

Amgen claims first US go-ahead for Humira biosimilar

Amjevita receives FDA approval but faces patent infringement lawsuit from AbbVie

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

- PMLiVE

Lundbeck challenge to EC pay-for-delay ruling fails

Court upholds €94m fine for paying off firms to delay launch of Celexa generics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links